CORRECTING and REPLACING Imalux® Names New President/CEO

CLEVELAND--(BUSINESS WIRE)--In the contact information, the area code for Thomas F. Barnish should read: 216 (sted 231).

The corrected release reads:

IMALUX^® NAMES NEW PRESIDENT/CEO

Imalux Corporation (“Imalux”), a medical device company and developer of the Niris^® Imaging System based on Optical Coherence Tomography (“OCT”) technology, today announced the election of Michael Burke as its President and Chief Executive Officer. He will also become a member of the Company’s Board of Directors.

Bill Sanford, Imalux Board Chairman, commented, “We are very pleased to have Mike assume the leadership role at Imalux. He has a track record of success in all phases of commercialization of medical technologies on a worldwide basis. In addition to his extensive experience in the health care imaging industry, Mike has an impressive combination of proven entrepreneurial and executive management skills with a diversified background ranging from start-ups to Fortune 100 companies. Mike is extremely well qualified to direct the Company through our next stages of accelerated growth.”

Mr. Burke’s thirty year health care industry career has included ten years in various domestic and international management positions at Scientific Products and American Hospital Supply Corporation (now Cardinal Health). At Picker International (now Philips Medical Systems) Mr. Burke was one of the founders of the Health Care Products Division which later became Source One. In 1995 he joined a private company, AccuMed International, and was key in taking AccuMed public.

In 1998 Mr. Burke led the acquisition of the microbiology assets of AccuMed, founding TREK Diagnostic Systems. Based upon an extensive market assessment, Mr. Burke had identified the unique market position a dedicated automated microbiology company could command. He recognized the technical superiority of his former employer’s products, their cadre of knowledgeable associates, and their loyal customer base. Mr. Burke succeeded in raising sufficient capital to invest in next generation versions of all main product lines and brought them to market, fueling TREK’s rapid and sustained growth.

In 2006 Mr. Burke arranged the sale of TREK to Magellan Bioscience, and chose to remain as CEO until November 2008. Today, with over 185 employees on two continents, TREK continues as a profitable, highly recognized brand in the global automated microbiology market and remains committed to delivering the highest quality products and services to clinical, pharmaceutical, and veterinary diagnostic laboratories worldwide.

Mr. Burke stated, “Following my TREK experience, I was looking at several opportunities for my next venture. As I did my due diligence on Imalux, I was greatly impressed by the strength and commitment of the Imalux team, the Company’s proprietary and proven technology, their excellent clinical validation studies, and, importantly, positive feedback from physicians using the Niris system. This combination indicates to me that the Company is well positioned to become a leader in the exciting and expanding OCT imaging market.”

About Imalux & the Niris Imaging System

Imalux Corporation, based in Cleveland, Ohio, is positioned to be a worldwide leader in the development and commercialization of site of care tissue imaging systems utilizing harmless, near-infrared light. The Imalux technology platform, sold under the Niris^® trademark, is based on our proprietary application of optical coherence tomography to provide real-time, high resolution, cross sectional imaging of tissue structures. Niris is a tool to aid in the diagnosis of disease, detection of cancer in its earliest stages, guidance of biopsy and surgery, and post-treatment surveillance in a multitude of clinical applications.